EdgarLookup

GAP INC — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that GAP INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
5.3%
Profit Margin
Net income ÷ revenue
6.5%
Return on Assets
Net income ÷ assets
+1.9%
Revenue Growth
Year over year

Revenue

Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.

Fiscal Year Period End Value Filed
FY2025 Jan 31, 2026 $15.37B Mar 17, 2026
FY2025 Feb 1, 2025 $15.09B Mar 17, 2026
FY2025 Feb 3, 2024 $14.89B Mar 17, 2026
FY2024 Jan 28, 2023 $15.62B Mar 18, 2025
FY2023 Jan 29, 2022 $16.67B Mar 19, 2024
FY2022 Jan 30, 2021 $13.80B Mar 14, 2023
FY2019 Feb 1, 2020 $4.67B Mar 17, 2020
FY2019 Nov 2, 2019 $4.00B Mar 17, 2020
FY2019 Aug 3, 2019 $4.01B Mar 17, 2020
FY2019 May 4, 2019 $3.71B Mar 17, 2020

Revenue (Net Sales)

Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.

Fiscal Year Period End Value Filed
FY2017 Feb 3, 2018 $4.78B Mar 20, 2018
FY2017 Oct 28, 2017 $3.84B Mar 20, 2018
FY2017 Jul 29, 2017 $3.80B Mar 20, 2018
FY2017 Apr 29, 2017 $3.44B Mar 20, 2018
FY2017 Jan 28, 2017 $4.43B Mar 20, 2018
FY2017 Oct 29, 2016 $3.80B Mar 20, 2018
FY2017 Jul 30, 2016 $3.85B Mar 20, 2018
FY2017 Apr 30, 2016 $3.44B Mar 20, 2018
FY2016 Jan 30, 2016 $4.39B Mar 20, 2017
FY2016 Oct 31, 2015 $3.86B Mar 20, 2017

Gross Profit

Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.

Fiscal Year Period End Value Filed
FY2025 Jan 31, 2026 $6.27B Mar 17, 2026
FY2025 Feb 1, 2025 $6.23B Mar 17, 2026
FY2025 Feb 3, 2024 $5.78B Mar 17, 2026
FY2024 Jan 28, 2023 $5.36B Mar 18, 2025
FY2023 Jan 29, 2022 $6.64B Mar 19, 2024
FY2022 Jan 30, 2021 $4.71B Mar 14, 2023
FY2019 Feb 1, 2020 $1.67B Mar 17, 2020
FY2019 Nov 2, 2019 $1.56B Mar 17, 2020
FY2019 Aug 3, 2019 $1.56B Mar 17, 2020
FY2019 May 4, 2019 $1.34B Mar 17, 2020

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 Jan 31, 2026 $816.00M Mar 17, 2026
FY2025 Feb 1, 2025 $844.00M Mar 17, 2026
FY2025 Feb 3, 2024 $502.00M Mar 17, 2026
FY2024 Jan 28, 2023 ($202.00M) Mar 18, 2025
FY2023 Jan 29, 2022 $256.00M Mar 19, 2024
FY2022 Jan 30, 2021 ($665.00M) Mar 14, 2023
FY2019 Feb 1, 2020 ($184.00M) Mar 17, 2020
FY2019 Nov 2, 2019 $140.00M Mar 17, 2020
FY2019 Aug 3, 2019 $168.00M Mar 17, 2020
FY2019 May 4, 2019 $227.00M Mar 17, 2020

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2025 Jan 31, 2026 $1.12B Mar 17, 2026
FY2025 Feb 1, 2025 $1.11B Mar 17, 2026
FY2025 Feb 3, 2024 $560.00M Mar 17, 2026
FY2024 Jan 28, 2023 ($69.00M) Mar 18, 2025
FY2023 Jan 29, 2022 $810.00M Mar 19, 2024
FY2022 Jan 30, 2021 ($862.00M) Mar 14, 2023
FY2021 Feb 1, 2020 $574.00M Mar 15, 2022
FY2020 Feb 2, 2019 $1.36B Mar 16, 2021
FY2019 Feb 3, 2018 $1.48B Mar 17, 2020
FY2018 Jan 28, 2017 $1.19B Mar 19, 2019

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2025 Jan 31, 2026 $60.00M Mar 17, 2026
FY2025 Feb 1, 2025 $40.00M Mar 17, 2026
FY2025 Feb 3, 2024 $37.00M Mar 17, 2026
FY2024 Jan 28, 2023 $46.00M Mar 18, 2025
FY2023 Jan 29, 2022 $41.00M Mar 19, 2024
FY2022 Jan 30, 2021 $46.00M Mar 14, 2023
FY2021 Feb 1, 2020 $41.00M Mar 15, 2022
FY2020 Feb 2, 2019 $50.00M Mar 16, 2021
FY2019 Feb 3, 2018 $51.00M Mar 17, 2020
FY2018 Jan 28, 2017 $46.00M Mar 19, 2019

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2025 Jan 31, 2026 $1.29B Mar 17, 2026
FY2025 Feb 1, 2025 $1.49B Mar 17, 2026
FY2025 Feb 3, 2024 $1.53B Mar 17, 2026
FY2024 Jan 28, 2023 $607.00M Mar 18, 2025
FY2023 Jan 29, 2022 $809.00M Mar 19, 2024
FY2022 Jan 30, 2021 $237.00M Mar 14, 2023
FY2021 Feb 1, 2020 $1.41B Mar 15, 2022
FY2020 Feb 2, 2019 $1.38B Mar 16, 2021
FY2019 Feb 3, 2018 $1.38B Mar 17, 2020
FY2018 Jan 28, 2017 $1.72B Mar 19, 2019

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2025 Jan 31, 2026 $470.00M Mar 17, 2026
FY2025 Feb 1, 2025 $447.00M Mar 17, 2026
FY2025 Feb 3, 2024 $420.00M Mar 17, 2026
FY2024 Jan 28, 2023 $685.00M Mar 18, 2025
FY2023 Jan 29, 2022 $694.00M Mar 19, 2024
FY2022 Jan 30, 2021 $392.00M Mar 14, 2023
FY2021 Feb 1, 2020 $702.00M Mar 15, 2022
FY2020 Feb 2, 2019 $705.00M Mar 16, 2021
FY2019 Feb 3, 2018 $731.00M Mar 17, 2020
FY2018 Jan 28, 2017 $524.00M Mar 19, 2019

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 Jan 31, 2026 $12.63B Mar 17, 2026
FY2025 Feb 1, 2025 $11.89B Mar 17, 2026
FY2024 Feb 3, 2024 $11.04B Mar 18, 2025
FY2023 Jan 28, 2023 $11.39B Mar 19, 2024
FY2022 Jan 29, 2022 $12.76B Mar 14, 2023
FY2021 Jan 30, 2021 $13.77B Mar 15, 2022
FY2020 Feb 1, 2020 $13.68B Mar 16, 2021
FY2019 Feb 2, 2019 $8.05B Mar 17, 2020
FY2018 Feb 3, 2018 $7.99B Mar 19, 2019
FY2017 Jan 28, 2017 $7.61B Mar 20, 2018

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 Jan 31, 2026 $3.80B Mar 17, 2026
FY2025 Feb 1, 2025 $3.26B Mar 17, 2026
FY2025 Feb 3, 2024 $2.60B Mar 17, 2026
FY2025 Jan 28, 2023 $2.23B Mar 17, 2026
FY2024 Jan 29, 2022 $2.72B Mar 18, 2025
FY2023 Jan 30, 2021 $2.61B Mar 19, 2024
FY2022 Feb 1, 2020 $3.32B Mar 14, 2023
FY2021 Feb 2, 2019 $3.55B Mar 15, 2022
FY2020 Feb 3, 2018 $3.14B Mar 16, 2021
FY2019 Jan 28, 2017 $2.90B Mar 17, 2020

Goodwill

An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.

Fiscal Year Period End Value Filed
FY2025 Jan 31, 2026 $207.00M Mar 17, 2026
FY2025 Feb 1, 2025 $207.00M Mar 17, 2026
FY2024 Feb 3, 2024 $207.00M Mar 18, 2025
FY2023 Jan 28, 2023 $207.00M Mar 19, 2024
FY2022 Jan 29, 2022 $207.00M Mar 14, 2023
FY2021 Jan 30, 2021 $109.00M Mar 15, 2022
FY2020 Feb 1, 2020 $109.00M Mar 16, 2021
FY2019 Feb 2, 2019 $109.00M Mar 17, 2020
FY2018 Feb 3, 2018 $109.00M Mar 19, 2019
FY2017 Jan 28, 2017 $109.00M Mar 20, 2018

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 Jan 31, 2026 $3.61B Mar 17, 2026
FY2025 Feb 1, 2025 $3.04B Mar 17, 2026
FY2024 Feb 3, 2024 $2.42B Mar 18, 2025
FY2023 Jan 28, 2023 $2.14B Mar 19, 2024
FY2022 Jan 29, 2022 $2.62B Mar 14, 2023
FY2021 Jan 30, 2021 $2.50B Mar 15, 2022
FY2020 Feb 1, 2020 $3.26B Mar 16, 2021
FY2019 Feb 2, 2019 $3.48B Mar 17, 2020
FY2018 Feb 3, 2018 $3.08B Mar 19, 2019
FY2017 Jan 28, 2017 $2.75B Mar 20, 2018

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2025 Jan 31, 2026 $2.62B Mar 17, 2026
FY2025 Feb 1, 2025 $2.34B Mar 17, 2026
FY2025 Feb 3, 2024 $1.87B Mar 17, 2026
FY2024 Jan 28, 2023 $1.22B Mar 18, 2025
FY2023 Jan 29, 2022 $877.00M Mar 19, 2024
FY2022 Jan 30, 2021 $1.99B Mar 14, 2023
FY2021 Feb 1, 2020 $1.36B Mar 15, 2022
FY2020 Feb 2, 2019 $1.08B Mar 16, 2021
FY2019 Feb 3, 2018 $1.78B Mar 17, 2020
FY2017 Jan 28, 2017 $1.78B Mar 20, 2018

Long-Term Debt

Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.

Fiscal Year Period End Value Filed
FY2017 Feb 3, 2018 $1.25B Mar 20, 2018
FY2017 Jan 28, 2017 $1.31B Mar 20, 2018
FY2016 Jan 30, 2016 $1.33B Mar 20, 2017
FY2015 Jan 31, 2015 $1.35B Mar 21, 2016
FY2014 Feb 1, 2014 $1.39B Mar 23, 2015
FY2013 Feb 2, 2013 $1.25B Mar 24, 2014
FY2012 Jan 28, 2012 $1.65B Mar 26, 2013

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 Jan 31, 2026 2 Mar 17, 2026
FY2025 Feb 1, 2025 2 Mar 17, 2026
FY2025 Feb 3, 2024 1 Mar 17, 2026
FY2024 Jan 28, 2023 0 Mar 18, 2025
FY2023 Jan 29, 2022 0 Mar 19, 2024
FY2022 Jan 30, 2021 (1) Mar 14, 2023
FY2019 Feb 1, 2020 0 Mar 17, 2020
FY2019 Nov 2, 2019 0 Mar 17, 2020
FY2019 Aug 3, 2019 0 Mar 17, 2020
FY2019 May 4, 2019 0 Mar 17, 2020

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 Jan 31, 2026 2 Mar 17, 2026
FY2025 Feb 1, 2025 2 Mar 17, 2026
FY2025 Feb 3, 2024 1 Mar 17, 2026
FY2024 Jan 28, 2023 0 Mar 18, 2025
FY2023 Jan 29, 2022 0 Mar 19, 2024
FY2022 Jan 30, 2021 (1) Mar 14, 2023
FY2019 Feb 1, 2020 0 Mar 17, 2020
FY2019 Nov 2, 2019 0 Mar 17, 2020
FY2019 Aug 3, 2019 0 Mar 17, 2020
FY2019 May 4, 2019 0 Mar 17, 2020

Shares Outstanding

Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.

Fiscal Year Period End Value Filed
FY2025 Jan 31, 2026 372.00M Mar 17, 2026
FY2025 Feb 1, 2025 374.00M Mar 17, 2026
FY2024 Feb 3, 2024 372.00M Mar 18, 2025
FY2023 Jan 28, 2023 366.00M Mar 19, 2024
FY2022 Jan 29, 2022 371.00M Mar 14, 2023
FY2021 Jan 30, 2021 374.00M Mar 15, 2022
FY2020 Feb 1, 2020 371.00M Mar 16, 2021
FY2019 Feb 2, 2019 378.00M Mar 17, 2020
FY2018 Feb 3, 2018 389.00M Mar 19, 2019
FY2017 Jan 28, 2017 399.00M Mar 20, 2018